berzosertib

Drug Overview

Berzosertib is an investigational drug being studied to treat several types of advanced cancer. It belongs to a modern class of medicines known as Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, berzosertib is a “Smart Drug” designed to block a specific protein that cancer cells use to stay alive.

In the world of oncology, berzosertib is often used alongside other treatments to make them work better. It acts like a “shield breaker,” preventing cancer cells from fixing themselves after they have been damaged by chemotherapy or radiation.

• Generic Name: Berzosertib (formerly known as M6620 or VX-970)
• US Brand Names: None (This drug is still in the testing phase)
• Drug Class: ATR Kinase Inhibitor / DNA Damage Response (DDR) Inhibitor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Investigational (Not yet approved for general use)

What Is It and How Does It Work? (Mechanism of Action)

To understand how berzosertib works, think of every cell in your body as having a “DNA repair kit.” When DNA—the instruction manual for the cell—gets damaged, the cell uses a protein called ATR kinase to pause and fix the damage.

Cancer cells grow and divide very quickly, which causes a lot of stress and damage to their DNA. They rely heavily on this ATR “repair kit” to survive. If the DNA isn’t fixed, the cell becomes too broken to function and dies.

At the molecular level, berzosertib works by:

1. Blocking the Repair Signal: It binds to the ATR protein and turns it off.
2. Stopping the “Pause” Button: Usually, ATR tells the cell to stop dividing while it fixes DNA. Berzosertib stops this message, forcing the cancer cell to keep dividing even though its DNA is broken.
3. Inducing “Mitotic Catastrophe”: Because the cancer cell continues to divide with shattered DNA, it eventually reaches a point of total collapse and undergoes apoptosis (programmed cell death).
4. Synthetic Lethality: This drug is especially effective in cancers that already have other “broken” repair proteins (like ATM or TP53 mutations), because the cell has no backup way to fix itself.

FDA-Approved Clinical Indications

As of early 2026, berzosertib is still being studied in clinical trials and does not have official FDA approval for standard use. However, it has shown great potential in the following areas:

Oncological Uses (Under Investigation)

• Ovarian Cancer: Specifically for patients with “platinum-resistant” ovarian cancer.
• Small Cell Lung Cancer (SCLC): Used in combination with other drugs to treat aggressive lung tumors.
• Non-Small Cell Lung Cancer (NSCLC): Studied in advanced cases with specific genetic markers.
• Stomach and Esophageal Cancer: Targeted toward tumors with TP53 mutations.

Non-Oncological Uses

• None. This drug is developed strictly for cancer treatment.

Dosage and Administration Protocols

Berzosertib is given as a liquid through a needle into a vein (IV). The dose is usually calculated based on your “Body Surface Area” (mg/m^2), which is a measurement of your height and weight.

Clinical Efficacy and Research Results

Research from 2020 to 2025 has focused on how berzosertib can “restart” the effectiveness of chemotherapy in patients whose cancer has stopped responding.

• Ovarian Cancer Success: In a major Phase II study, adding berzosertib to a standard drug (gemcitabine) significantly increased the time patients lived without their cancer growing compared to gemcitabine alone.
• Lung Cancer Response: In trials for advanced squamous cell lung cancer, about 46% of patients saw their tumors shrink when berzosertib was added to their treatment plan.
• Precision Medicine: Results show the drug is most effective in patients with specific “DDR” (DNA Damage Response) markers, such as a loss of the ATM protein.

Safety Profile and Side Effects

Because berzosertib prevents cells from repairing themselves, it can affect healthy cells that divide quickly, like those in your bone marrow.

Common Side Effects (>10%)

• Anemia (Low Red Blood Cells): Can make you feel very tired or short of breath.
• Neutropenia (Low White Blood Cells): Increases the risk of getting an infection.
• Thrombocytopenia (Low Platelets): Makes it easier for you to bruise or bleed.
• Fatigue: A general feeling of weakness or exhaustion.
• Nausea: Feeling like you might vomit.

Serious Adverse Events

• Severe Myelosuppression: A dangerous drop in blood counts that may require a transfusion.
• Gastric Hemorrhage: Rare but serious internal bleeding in the stomach area.
• Infusion Reactions: Mild fever or chills during the IV treatment.

Management Strategies

• Regular Blood Checks: Your doctor will test your blood often to catch low counts before they become dangerous.
• Preventative Meds: You may be given medicine to help prevent nausea before your treatment begins.

Research Areas

Current research is exploring how berzosertib can be combined with other new types of treatment. This includes combining it with Immunotherapy (like pembrolizumab) to see if breaking down cancer’s DNA makes it easier for the immune system to find and kill the tumor. Scientists are also looking at using it in “precision medicine” trials where only patients with specific genetic mutations in their tumors are treated, ensuring the drug is used where it has the best chance of working.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Complete Blood Count (CBC): To check your red cells, white cells, and platelets.
• Genetic Testing: To see if your tumor has the specific “repair kit” markers that make berzosertib effective.
• Liver and Kidney Function: Standard blood tests to ensure your body can handle the medication.

Precautions During Treatment

• Avoid Pregnancy: This drug can harm an unborn baby. Use effective birth control during and for several months after treatment.
• Monitor for Infection: Tell your doctor immediately if you have a fever over 100.4°F (38°C) or chills.

“Do’s and Don’ts”

• Do stay hydrated by drinking plenty of water.
• Do rest when you feel tired; your body is working hard to fight the cancer.
• Don’t take any new vitamins or herbal supplements without asking your oncology team first.
• Don’t ignore unusual bruising or small red spots on your skin.

Legal Disclaimer

This guide is for informational purposes only and is not medical advice. Berzosertib is an investigational drug and is not yet approved by the FDA for general use. Treatment decisions should only be made with a qualified oncologist. Always talk to your doctor about the risks and benefits of participating in a clinical trial.